Skip to main content

Advertisement

SpringerLink
Log in

Role of Novel Biological Therapies in Psoriatic Arthritis

Effects on Joints and Skin

  • Therapy Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA) is a partly debilitating disease that may affect small and large joints and the spine. Patients with PsA are divided into different subgroups according to joint involvement and their disease may be classified as part of the spectrum of spondyloarthritides or seronegative rheumatoid arthritis. Traditional treatment comprises nonsteroidal anti-inflammatory drugs, systemic and intra-articular corticosteroids and disease-modifying antirheumatic drugs such as sulfasalazine, methotrexate and cyclosporin. On the basis of the very recent studies performed in the US and Germany, patients with severe disease can be treated with anti-tumour necrosis factor (TNF) therapy. Biologicals such as etanercept and infliximab have been used successfully to treat PsA. While etanercept is a 75kD TNF receptor fusion protein that binds to TNFα and TNFβ, infliximab is a chimeric monoclonal antibody that binds to TNFα both in its soluble form in the serum and on the cell membrane. Adalimumab is a fully humanised antibody recognising TNFα that has not been tested in PsA to date. Another biological agent, alefacept, is directed against the adhesion molecule lymphocyte function-associated antigen (LFA)-2, which is known to interfere with T-cell activation. Alefacept has been shown to be efficacious in a limited number of patients with PsA. Taken together, there has been definite recent progress in the treatment of PsA. Severely affected patients may especially have substantial benefit from therapy with biologicals directed against TNFα and other targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The ‘Weber effect’ refers to the observation that the peak of spontaneous reporting of adverse events for a drug is at the end of the second year of marketing, and reporting declines later.

References

  1. Gladman DD, Stafford-Brady F, ChangC-H, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809–12

    PubMed  CAS  Google Scholar 

  2. Torre-Alonso JC, Rodriguez Perez A, Arribas CastrilloJM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245–50

    PubMed  CAS  Google Scholar 

  3. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software; 2001

    Google Scholar 

  4. Robert C, Kupper TS. Psoriasis: inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 1999; 341: 1817–28

    PubMed  CAS  Google Scholar 

  5. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518–23

    PubMed  CAS  Google Scholar 

  6. Husby G, Williams RC Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1: 363–71

    PubMed  CAS  Google Scholar 

  7. Deleuran BW, Chu CQ, Field M, et al. Localization of interleukin-lα, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992; 31: 801–9

    PubMed  CAS  Google Scholar 

  8. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544–52

    PubMed  CAS  Google Scholar 

  9. Nawroth PP, Bank I, Handley D, et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363–75

    PubMed  CAS  Google Scholar 

  10. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; II: 244–7

    Google Scholar 

  11. Butler DM, Maini RN, Feldmann M, et al. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995; 6: 225–30

    PubMed  CAS  Google Scholar 

  12. Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991; 21: 2575–9

    PubMed  CAS  Google Scholar 

  13. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547–9

    PubMed  CAS  Google Scholar 

  14. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516–8

    PubMed  CAS  Google Scholar 

  15. Shinmei M, Masuda K, Kikuchi T, et al. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol 1989; 6Suppl. 18: 32–4

    Google Scholar 

  16. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163–8

    PubMed  CAS  Google Scholar 

  17. Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105–10

    PubMed  CAS  Google Scholar 

  18. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160–9

    PubMed  CAS  Google Scholar 

  19. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485–9

    PubMed  CAS  Google Scholar 

  20. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548–61

    PubMed  CAS  Google Scholar 

  21. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993 Dec; 36(12): 1681–90

    PubMed  CAS  Google Scholar 

  22. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344(8930): 1105–10

    PubMed  CAS  Google Scholar 

  23. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994 Oct 22; 344(8930): 1125–7

    PubMed  CAS  Google Scholar 

  24. Maini RN, Elliott MJ, Brennan FM, et al. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995 Apr; 144: 195–223

    PubMed  CAS  Google Scholar 

  25. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602

    PubMed  CAS  Google Scholar 

  26. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) —Fc fusion protein. N Engl J Med 1997; 337: 141–8

    PubMed  CAS  Google Scholar 

  27. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93

    PubMed  CAS  Google Scholar 

  28. Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52

    PubMed  CAS  Google Scholar 

  29. Brandt J, Haibel H, Reddig J, et al. Treatment of patients with severe ankylosing spondylitis with infliximab: a one year follow up. Arthritis Rheum 2001; 44(12): 2936–7

    PubMed  CAS  Google Scholar 

  30. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a double-blind placebo controlled multicenter trial. Lancet 2002; 359: 1187–93

    PubMed  CAS  Google Scholar 

  31. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000 Jun; 59(6): 428–33

    PubMed  Google Scholar 

  32. Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002; 46: 755–65

    Google Scholar 

  33. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001 Jul; 28(7): 1605–14

    PubMed  CAS  Google Scholar 

  34. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959–65

    PubMed  CAS  Google Scholar 

  35. Antoni C, Dechant C, Ogilvie A, et al. Successful treatment of psoriatic arthritis with infliximab in an MRI controlled study [abstract]. J Rheumatol 2000; 27Suppl. 59: 24

    Google Scholar 

  36. Antoni C, Dechant C, Lorenz HM, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Res 2002; 47: 506–12

    CAS  Google Scholar 

  37. Marzo-Ortega H, McGonagle D, O’Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001 Sep; 44(9): 2112–7

    PubMed  CAS  Google Scholar 

  38. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002 May 2; 346(18): 1349–56

    PubMed  CAS  Google Scholar 

  39. Brandt J, Haibel H, Reddig J, et al. Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab. J Rheumatol 2002; 29: 118–22

    PubMed  CAS  Google Scholar 

  40. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356(9244): 1821–2

    PubMed  Google Scholar 

  41. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499–505

    PubMed  CAS  Google Scholar 

  42. Mielants H, Veys EM, Goemaere S, et al. A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. J Rheumatol 1993 Aug; 20(8): 1353–8

    PubMed  CAS  Google Scholar 

  43. Sandborn WJ. Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999; 5: 119–33

    PubMed  CAS  Google Scholar 

  44. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001 Nov; 121(5): 1088–94

    PubMed  CAS  Google Scholar 

  45. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001 May; 7(2): 83–8

    PubMed  CAS  Google Scholar 

  46. Lichtenstein GR. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001 May; 7(2): 89–93

    PubMed  CAS  Google Scholar 

  47. Krueger GG. Selective targeting of T cell subsets: focus on alefacept — a remittive therapy for psoriasis. Expert Opin Biol Ther 2002 Apr; 2(4): 431–41

    PubMed  CAS  Google Scholar 

  48. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD 16 signaling and CD2/ CD16-dependent apoptosis of CD2 (+) cells. J Immunol 2002 May 1; 168(9): 4462–71

    Google Scholar 

  49. Lebwohl M, Ali S. Treatment of psoriasis: Part 1. topical therapy and phototherapy. J Am Acad Dermatol 2001 Oct; 45(4): 487–98

    PubMed  CAS  Google Scholar 

  50. Lebwohl M, Ali S. Treatment of psoriasis: Part 2. systemic therapies. J Am Acad Dermatol 2001 Nov; 45(5): 649–61

    PubMed  CAS  Google Scholar 

  51. Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care 2002 Apr; 8(6 Suppl.): S160–70

    PubMed  Google Scholar 

  52. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002 Apr; 61(4): 298–304

    PubMed  CAS  Google Scholar 

  53. Ruddle NH. Lymphoid neo-organogenesis: lymphotoxin’s role in inflammation and development. Immunol Res 1999; 19: 119–25

    PubMed  CAS  Google Scholar 

  54. Barone D, Krantz C, Lambert D, et al. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion [abstract]. Arthritis Rheum 1999; 42 Suppl.: S90

    Google Scholar 

  55. Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 2001 Nov; 60 Suppl. 3: iii37–40

    Google Scholar 

  56. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90

    PubMed  CAS  Google Scholar 

  57. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013–20

    PubMed  CAS  Google Scholar 

  58. Felson DT, Andersen JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35

    PubMed  CAS  Google Scholar 

  59. Mease PJ, Goffe BS, Metz J, et al. Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis. Ann Rheum Dis 2001; 60Suppl. I: 146

    Google Scholar 

  60. Mease P, Kivitz A, Burch F, et al. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001; 44 Suppl.: S90

    Google Scholar 

  61. Gottlieb AB, Lowe NJ, Matheson RT, et al. Efficacy of etanercept in patients with psoriasis. Presented at: American Academy of Dermatology; 2002 Feb 24–26; New Orleans (LA)

  62. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118–21

    PubMed  CAS  Google Scholar 

  63. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732–4

    PubMed  CAS  Google Scholar 

  64. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years [letter]. Clin Exp Rheumatol 2002; 20: 115

    PubMed  CAS  Google Scholar 

  65. Elkayam O, Yaron M, Caspi D. From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept [letter]. Ann Rheum Dis 2000; 59: 839

    PubMed  CAS  Google Scholar 

  66. Kurschat P, Rubbert A, Poswig A, et al. Treatment of psoriatic arthritis with etanercept [letter]. J Am Acad Dermatol 2001; 44: 1052

    PubMed  CAS  Google Scholar 

  67. Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 1093–8

    PubMed  CAS  Google Scholar 

  68. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207–12

    PubMed  CAS  Google Scholar 

  69. Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001 Mar; 144(3): 587–9

    PubMed  CAS  Google Scholar 

  70. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000 May; 42(5 Pt 1): 829–30

    PubMed  CAS  Google Scholar 

  71. Kirby B, Marsland AM, Carmichael AJ, et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001 Jan; 26(1): 27–9

    PubMed  CAS  Google Scholar 

  72. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 Jun 9; 357(9271): 1842–7

    PubMed  CAS  Google Scholar 

  73. O’Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002 May; 138(5): 644–8

    PubMed  Google Scholar 

  74. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002 Jun; 46(6): 886–91

    PubMed  Google Scholar 

  75. Salvarani C, Cantini F, Olivieri I, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Care Res 2003. In press

  76. Olivieri I, Padula A, Ciancio G, et al. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61: 375–6

    PubMed  CAS  Google Scholar 

  77. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in Inflammation Research. Vol 6. New York: Raven Press, 1984: 1–7

    Google Scholar 

  78. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct 11; 345(15): 1098–104

    PubMed  CAS  Google Scholar 

  79. Keane J, Gershon SK, Braun M. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346(8): 625–6

    Google Scholar 

  80. Riminton S, Pearce N, Basten A. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346(8): 625

    Google Scholar 

  81. Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346(8): 623–6

    PubMed  Google Scholar 

  82. Bean GA, Rosch DR, Briscoe H, et al. Structural deficiences in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol mycobacterium tuberculosis infection. J Immunol 1999; 162: 3504–11

    PubMed  CAS  Google Scholar 

  83. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346(8): 625

    Google Scholar 

  84. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997 Jan 18; 349(9046): 170–3

    PubMed  CAS  Google Scholar 

  85. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn’s disease [letter]. Inflamm Bowel Dis 2001 Nov; 7(4): 327

    PubMed  CAS  Google Scholar 

  86. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy [letter]. Ann Intern Med 2002 Jan 15; 136(2): 174

    PubMed  Google Scholar 

  87. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis [letter]. Lancet 2001 Nov 24; 358(9295): 1784

    PubMed  CAS  Google Scholar 

  88. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001 Jun; 76(6): 653–6

    PubMed  CAS  Google Scholar 

  89. Zhang Z, Correa H, Bégué RE. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346(8): 624

    Google Scholar 

  90. Warns A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001 Apr 5; 344(14): 1099–100

    Google Scholar 

  91. Phillips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002 Feb; 47(1): 17–21

    PubMed  CAS  Google Scholar 

  92. De Rosa FG, Bonora S, Di Perri G. Tuberculosis and treatment with infliximab [letter]. N Engl J Med 2002; 346(8): 624

    Google Scholar 

  93. Moreland LW, Cohen SB, Baumgartner SW, et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28:1238–44

    PubMed  CAS  Google Scholar 

  94. Kavanaugh A, Keenan G, DeWoody K, et al. Long-term follow-up of patients treated with Remicade (Infliximab) in clinical trials [abstract]. Arthritis Rheum 2001; 46: S173

    Google Scholar 

  95. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001 Dec; 45(6): 953–6

    PubMed  CAS  Google Scholar 

  96. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44(12): 2862–9

    PubMed  CAS  Google Scholar 

  97. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996 Dec; 47(6): 1531–4

    Google Scholar 

  98. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with TNF-α antagonism: by what mechanisms could TNF-α antagonism improve RA but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977–83

    PubMed  CAS  Google Scholar 

  99. Data on file, Centocor

  100. FDA website, http://www.fda.gov

  101. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000 Nov; 43(11): 2606–8

    PubMed  CAS  Google Scholar 

  102. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000 Aug; 27(8): 2041–4

    PubMed  CAS  Google Scholar 

  103. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002 Jan; 41(1): 116–7

    CAS  Google Scholar 

  104. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002 Feb 16; 359( 9306): 579–80

    PubMed  CAS  Google Scholar 

  105. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with RA. J Rheumatol 2002; 29: 667–77

    PubMed  CAS  Google Scholar 

  106. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348(7): 601–8

    PubMed  CAS  Google Scholar 

  107. Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 Jul 26; 345(4): 248–55

    PubMed  CAS  Google Scholar 

  108. Dinant HJ, van Kuijk AWR, Goedkoop AY, et al. Alefacept (LFA3-IgGl fusion protein LFA3TIP) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis. Arthritis Rheum 2001; 42 Suppl.: S91

    Google Scholar 

  109. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002 May; 138(5): 591–600

    PubMed  CAS  Google Scholar 

  110. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000 Sep; 43(3): 448–58

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Professors Braun and Sieper are members of advisory boards of the following companies: Centocor, Schering-Plough, Wyeth, Amgen, Abbott.

Author information

Authors and Affiliations

  1. Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652, Herne, Germany

    Juergen Braun

  2. Medical Department I, Rheumatology, University Hospital Benjamin Franklin, Berlin, Germany

    Joachim Sieper

Authors
  1. Juergen Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joachim Sieper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juergen Braun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braun, J., Sieper, J. Role of Novel Biological Therapies in Psoriatic Arthritis. BioDrugs 17, 187–199 (2003). https://doi.org/10.2165/00063030-200317030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200317030-00005

Keywords

Search

Navigation